NEXTSTELLIS® revenue was US$14.1m vs US$4.2m in FY22 with sales momentum building. Dispensed cycles were up 2.5x July 2023 v July 2022 and up 80% in 2HFY23 vs 1HFY23 attributable to the positive impact of our refreshed leadership and marketing strategy.2 days agoMore than 3 fold revenue growth proves the company strategy success , with 75% reduction in marketing costs YOY , with the same rate , FY24 could reach 45 m to 50 Mil THEN so yes they are on the path to profitability . all indictors are positive .Share price outlook , if after the feb update that was 97 m worse the price reached 4.9 then after the +ve update expect 6 to 7 to 8.85 as per gauldman schs analysts
- Forums
- ASX - By Stock
- MYX
- Generated positive operating cash flow
MYX
mayne pharma group limited
Add to My Watchlist
2.18%
!
$5.16

Generated positive operating cash flow, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.16 |
Change
0.110(2.18%) |
Mkt cap ! $419.2M |
Open | High | Low | Value | Volume |
$5.00 | $5.16 | $4.80 | $2.951M | 587.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3000 | $5.10 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.16 | 576 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 5.020 |
1 | 1000 | 5.000 |
1 | 3500 | 4.960 |
2 | 5916 | 4.910 |
1 | 320 | 4.880 |
Price($) | Vol. | No. |
---|---|---|
5.160 | 576 | 3 |
5.190 | 5000 | 1 |
5.200 | 20200 | 2 |
5.250 | 75 | 1 |
5.270 | 5000 | 1 |
Last trade - 16.10pm 21/07/2025 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |